Drug intelligence / Profile preview

iPD1 CD19 eCAR T cells (Peking University)

Development stage: Unknown
Lead developer: Beijing Mali Biotechnology
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies
Administration: Intravenous

Overview

iPD1 CD19 eCAR T cells is an autologous, fourth-generation ("armored") chimeric antigen receptor (CAR) T-cell therapy developed by Peking University for the treatment of relapsed or refractory B-cell lymphoma. The therapy consists of patient-derived T cells genetically engineered using a lentiviral vector to express a second-generation CAR targeting the CD19 antigen (utilizing a 4-1BB costimulatory domain) alongside a short hairpin RNA (shRNA) cassette designed to knockdown the expression of Programmed Cell Death Protein 1 (PD1). By incorporating intrinsic PD1 inhibition, the therapy aims to prevent the induction of the PD1/PD-L1 immunosuppressive pathway upon T-cell activation, thereby enhancing the persistence and anti-tumor activity of the CAR T cells within the tumor microenvironment. It is currently being evaluated in Phase 1 clinical trials.

Other names: iPD1 CD19 eCAR T cellsiPD-1 CD19 eCAR T cellsiPD 1 CD19 eCAR T cellsAutologous Anti-CD19 4-1BB CAR T Cells With Cell-intrinsic PD1 InhibitioniPD1-CD19-eCAR-TiPD-1-CD19-eCAR-TiPD 1-CD19-eCAR-T

Targets

CD19 (B lymphocyte antigen CD19)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on iPD1 CD19 eCAR T cells (Peking University).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iPD1 CD19 eCAR T cells (Peking University).

Explore the full profile